Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients

Clinical Nephrology

Volumn 63, Issue 6, 2005, Pages 454-460

  Staniforth, M E ^a   Cheng, S C ^a   Coyne, D W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium; Hemodialysis; Hyperparathyroidism; Osteodystrophy; Phosphorus; Vitamin D

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MALE; NONHUMAN; NURSING; PARATHYROID HORMONE BLOOD LEVEL; PATIENT MONITORING; PHOSPHATE BLOOD LEVEL; POPULATION RESEARCH; SECONDARY HYPERPARATHYROIDISM; STATISTICAL SIGNIFICANCE;

EID: 21044442897     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP63454     Document Type: Article

References (24)

1. Andress DL 2001 Intravenous versus oral vitamin D therapy in dialysis patients: what is the question? Am J Kidney Dis 38: S41-44
2. Block GA 2000 Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol 54: 318-324
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. 1998 Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607-617
4. 3 in normal and uraemic men. Nephrol Dial Transplant 17: 829-842
5. Brown AJ, Finch J, Slatopolsky E 2002 Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D 3 on intestinal calcium and phosphate transport. J Lab Clin Med 139: 279-284
6. Cato A 3rd, Cady WW, Soltanek C, Qasawa B, Chang M, Stoll R 1998 Effect of hemodialysis on the pharmacokinetics of 19-nor-1alpha,25-dihydroxyvitamin D2. Am J Kidney Dis 32: S55-60
7. Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E 2002 Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40: 1283-1288
8. Foundation NK 2003 Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42: S1-S202
9. Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G 1992 Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 42: 1191-1198
10. Gallieni M, Brancaccio D, Antonucci F, Bellinghieri G, Carpani P, Cozzolino M, D'Agostino F, Del Mastro G, Mallamace A, Memoli B 2000 Twice- versus thrice-weekly administration of intravenous calcitriol in dialysis patients: a randomized prospective trial. Gruppo Italiano di Studio dell'Osteodistrofia Renale. Clin Nephrol 53: 188-193
11. Goodman WG 2003 Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 18 Suppl 3: iii2-8
12. Lindberg J 2001 A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clinical Nephrology 56: 315-323
13. Llach F, Fernandez E 2003 Overview of renal bone disease: causes of treatment failure, clinical observations, the changing pattern of bone lesions, and future therapeutic approach. Kidney Int Suppl: S113-119
14. Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E 1998 Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis 32: S48-54
15. Llach F, Yudd M 2001 Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38: S45-50
16. Martin KJ, Gonzalez E, Lindberg JS, Taccetta C, Amdahl M, Malhotra K, Llach F 2001 Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis 38: S57-63
17. Maxwell DR, Benjamin DM, Donahay SL, Allen MK, Hamburger RJ, Luft FC 1978 Calcitriol in dialysis patients. Clin Pharmacol Ther 23: 515-519
18. Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F 1991 The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 2: 1014-1020
19. Silver J, Kilav R, Naveh-Many T 2002 Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 283: F367-376
20. Slatopolsky E, Brown A, Dusso A 1999a Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73: S14-19
21. Slatopolsky E, Dusso A, Brown A 1999b New analogs of vitamin D3. Kidney Int Suppl 73: S46-51
22. Slatopolsky E, Brown A, Dusso A 2001 Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37: S54-57
23. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D 2003 Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63: 1483-1490
24. Stim JA, Lowe J, Arruda JA, Dunea G 1995 Once-weekly intravenous calcitriol suppresses hyperparathyroidism in hemodialysis patients. Asaio J 41: M693-698